Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

Article Biochemistry & Molecular Biology

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative

Thomas K. Karikari et al.

Summary: Plasma phosphorylated-tau181 (p-tau181) is a promising blood-based biomarker specific for Alzheimer's disease (AD), showing high diagnostic accuracy and increasing levels with disease progression.

MOLECULAR PSYCHIATRY (2021)

添加到收藏夹

Article Clinical Neurology

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

Joel Simren et al.

Summary: P-tau181 shows potential as an effective diagnostic and prognostic biomarker in AD, detecting the disease at MCI and dementia stages and being strongly associated with cognitive decline and gray matter loss.

ALZHEIMERS & DEMENTIA (2021)

添加到收藏夹

Article Clinical Neurology

Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum

Alexis Moscoso et al.

Summary: Measurement of tau phosphorylated at threonine 181 (p-tau181) in blood plasma is proposed as a specific biomarker for Alzheimer's disease. Longitudinal study reveals that plasma p-tau181 increases before amyloid-beta markers reach abnormal levels, correlating with amyloid-beta pathology. Plasma p-tau181 also shows associations with widespread cortical tau aggregation and may be a useful diagnostic and screening tool for Alzheimer's disease.

BRAIN (2021)

添加到收藏夹

Article Neurosciences

Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome

Melissa E. Petersen et al.

Summary: This study investigated the diagnostic performance of plasma neurofilament light chain (Nf-L) and total-tau in distinguishing cognitive status among adults with Down syndrome (DS). The results indicated that Nf-L and total-tau could serve as useful biomarkers for both AD pathology and clinical status in DS, potentially becoming outcome measures in clinical trials for disease-modifying drugs in the future.

JOURNAL OF ALZHEIMERS DISEASE (2021)

添加到收藏夹

Article Clinical Neurology

Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease

Ignacio Illan-Gaia et al.

Summary: Plasma NfL outperforms plasma t-tau in distinguishing between FTLD-S and AD-S, predicting clinical decline and survival, and correlating with regional cortical thickness; while plasma t-tau shows inferior performance in these aspects.

NEUROLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition

Nicholas C. Cullen et al.

Summary: The study revealed that inflammatory proteins in both cerebrospinal fluid (CSF) and plasma are associated with cognitive impairment and AD pathology. The levels of inflammatory proteins varied across different stages of AD, with CSF inflammatory changes highly correlated with core AD biomarkers.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Clinical Neurology

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

Alexis Moscoso et al.

Summary: This study found that plasma p-tau181 could serve as a marker for predicting and monitoring neurodegeneration and cognitive decline, with greater AD specificity compared to plasma NfL, holding important implications for monitoring AD progression in clinical practice and treatment trials.

JAMA NEUROLOGY (2021)

添加到收藏夹

Article Psychiatry

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease

Pratishtha Chatterjee et al.

Summary: The study found that plasma GFAP levels are elevated in cognitively normal older adults at risk of AD, indicating that astrocytic damage or activation may start from the pre-symptomatic stage of the disease and is associated with brain Aβ load. The potential of plasma GFAP to contribute to a diagnostic blood biomarker panel, along with plasma Aβ 1-42/Aβ 1-40 ratios, for cognitively normal older adults at risk of AD was highlighted by the observations from the present study.

TRANSLATIONAL PSYCHIATRY (2021)

添加到收藏夹

Article Clinical Neurology

Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients

C. Bridel et al.

Summary: The study suggests that variations in neurofilament light occur to a similar extent and magnitude in both healthy controls and multiple sclerosis populations. Changes between two consecutive neurofilament light measurements may reflect natural fluctuations rather than variations in inflammatory disease activity.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology

Nicholas J. Ashton et al.

Summary: Plasma phosphorylated tau231 is a promising biomarker for detecting Alzheimer's disease, accurately distinguishing AD patients from others and showing potential for early detection of pathology. Its performance is strong across various disease settings and it correlates well with other indicators of AD progression.

ACTA NEUROPATHOLOGICA (2021)

添加到收藏夹

Article Clinical Neurology

Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study

Adam M. Brickman et al.

Summary: Blood-based Alzheimer's disease biomarkers show associations with pathological and clinical diagnoses, and have predictive value for future development of clinical AD, indicating their potential for incorporation into multi-ethnic community studies.

ALZHEIMERS & DEMENTIA (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

N. J. Ashton et al.

Summary: The development of blood biomarkers for Alzheimer's disease has shown promise for dementia diagnosis and early detection. Plasma p-tau has demonstrated analytical and clinical validity, while A beta's maturity level remains partially achieved. Despite progress in phases 1 through 3, more data is needed on covariate effects on biomarker measurement.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Review Medicine, General & Internal

Alzheimer's disease

Philip Scheltens et al.

Summary: Alzheimer's disease is projected to see a significant increase in prevalence in the future, with genetics playing a key role. Novel biomarkers and lifestyle-based prevention trials show promising therapeutic potential. Promising pharmacological treatments are advancing in clinical trials, targeting amyloid beta, tau, and inflammation.

LANCET (2021)

添加到收藏夹

Article Clinical Neurology

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

Shorena Janelidze et al.

Summary: This study highlights the potential of plasma P-tau217 as an early biomarker for Alzheimer's disease, showing elevated levels before tau-PET detected insoluble tau aggregates. Modeling suggests that changes in plasma and CSF P-tau217 precede tau-PET signals, indicating its usefulness in detecting early AD brain pathology.

JAMA NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Oskar Hansson et al.

Summary: To address variability in measurements across laboratories, a workgroup led by the Alzheimer's Association developed a simplified and standardized pre-analytical protocol for CSF collection and handling, aiming to improve AD diagnostic accuracy and reduce patient misclassification rates.

ALZHEIMERS & DEMENTIA (2021)

添加到收藏夹

Article Neurosciences

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

Tim West et al.

Summary: The development of a high-resolution mass spectrometry-based plasma biomarker test shows strong diagnostic performance in distinguishing brain amyloid status for Alzheimer's disease and may enhance the efficiency of enrolling participants into AD drug trials.

MOLECULAR NEURODEGENERATION (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease

Elisabeth H. Thijssen et al.

Summary: Plasma biomarkers reflecting specific Abeta proteoforms can provide valuable insights into the treatment effects of Alzheimer's disease therapies. The newly developed Amyblood assays showed similar technical and clinical performance as commercial assays, but exhibited better specificity and selectivity, making them promising for monitoring treatment response in clinical trials.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Clinical Neurology

A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study

E. A. J. Willemse et al.

Summary: The study evaluated the clinical use of serum neurofilament light in a tertiary memory clinic setting, finding it to be more useful for patients below 62 years old and males.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Article Clinical Neurology

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Claudiaf Cicognola et al.

Summary: Plasma GFAP can detect AD pathology in patients with MCI and predict conversion to AD dementia, showing potential clinical utility.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Article Clinical Neurology

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

Elisabeth H. Thijssen et al.

Summary: Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau phosphorylated at threonine 181 (p-tau181) showed excellent diagnostic performance in distinguishing patients with Alzheimer's disease syndromes from other neurodegenerative disorders. P-tau217 outperformed p-tau181 in differentiating Alzheimer's disease syndromes from FTLD syndromes, indicating amyloid-PET positivity, and showing stronger correlations with tau-PET signal.

LANCET NEUROLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Biomarkers for neurodegenerative diseases

Oskar Hansson

Summary: Biomarkers for neurodegenerative diseases play a crucial role in improving diagnostic workup and therapy monitoring, with emerging blood-based markers and discussions on their implementation in clinical practice and trials.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

Sebastian Palmqvist et al.

Summary: Plasma P-tau, in combination with plasma phospho-tau and other biomarkers, along with clinical tests and APOE genotyping, can accurately predict the risk of Alzheimer's disease dementia, improving diagnostic prediction and facilitating recruitment for clinical trials.

NATURE MEDICINE (2021)

添加到收藏夹

Article Clinical Neurology

Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes

Michelle M. Mielke et al.

Summary: This study analyzed data from the Mayo Clinic Study on Aging conducted from 2015 to 2017, and found subtle differences in predicting cerebrovascular and Alzheimer-related pathology between different plasma p-tau species and measurement platforms. Some p-tau species were associated with white matter hyperintensity volume and white matter microstructural integrity.

JAMA NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype

Antoinette O'Connor et al.

Summary: In this study, differences in amyloid-beta processing between PSEN1 and APP carriers were identified, providing insights into disease pathophysiology and potential implications for therapy development. The analysis of plasma and cell line models demonstrated consistent amyloid-B profiles, with associations found between A beta 42:38, AB42:40, and A beta 38:40 ratios and parental age at onset in the PSEN1 group.

BRAIN (2021)

添加到收藏夹

Article Geriatrics & Gerontology

Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study

Inge M. W. Verberk et al.

Summary: This study aimed to evaluate the prognostic and monitoring value of serum GFAP and NfL for progression to dementia in individuals with normal cognition. Results showed that high baseline levels of GFAP and NfL were associated with an increased risk of dementia, with GFAP potentially serving as a valuable prognostic biomarker and NfL as a monitoring biomarker.

LANCET HEALTHY LONGEVITY (2021)

添加到收藏夹

Article Clinical Neurology

Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's

Fanny M. Elahi et al.

ALZHEIMERS & DEMENTIA (2020)

添加到收藏夹

Article Clinical Neurology

Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

Carolin Heller et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Shorena Janelidze et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration

Elisabeth H. Thijssen et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Geriatrics & Gerontology

Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project

Inge M. W. Verberk et al.

NEUROBIOLOGY OF AGING (2020)

添加到收藏夹

Review Behavioral Sciences

Obesity affects brain structure and function- rescue by bariatric surgery?

Minke H. C. Nota et al.

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results

Emily A. Largent et al.

PLOS ONE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Serum neurofilament light levels in normal aging and their association with morphologic brain changes

Michael Khalil et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Review Clinical Neurology

Neurofilaments: neurobiological foundations for biomarker applications

Arie R. Gafson et al.

BRAIN (2020)

添加到收藏夹

Article Clinical Neurology

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels

Ali Manouchehrinia et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Shorena Janelidze et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Clinical Neurology

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification

Nicolas R. Barthelemy et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

添加到收藏夹

Article Clinical Neurology

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts

Thomas K. Karikari et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease

Nicolas R. Barthelemy et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Clinical Neurology

Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

Juan Lantero Rodriguez et al.

ACTA NEUROPATHOLOGICA (2020)

添加到收藏夹

Article Medicine, General & Internal

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Sebastian Palmqvist et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Clinical Neurology

Comparing progression biomarkers in clinical trials of early Alzheimer's disease

Nicholas C. Cullen et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)

添加到收藏夹

Article Immunology

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease

Nicolas R. Barthelemy et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

添加到收藏夹

Article Clinical Neurology

Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration

Alberto Benussi et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

添加到收藏夹

Article Clinical Neurology

Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study

Kumar B. Rajan et al.

ANNALS OF NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study

Yakeel T. Quiroz et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease

Niklas Mattsson-Carlgren et al.

BRAIN (2020)

添加到收藏夹

Article Neurosciences

Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage

Breton M. Asken et al.

JOURNAL OF ALZHEIMERS DISEASE (2020)

添加到收藏夹

Article Neurosciences

Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration

Alberto Benussi et al.

JOURNAL OF ALZHEIMERS DISEASE (2020)

添加到收藏夹

Article Neurosciences

Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease

Yen Ying Lim et al.

JOURNAL OF ALZHEIMERS DISEASE (2020)

添加到收藏夹

Article Clinical Neurology

Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Inge M. W. Verberk et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease

Hendrik Wesseling et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals

Jasmeer P. Chhatwal et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Clinical Neurology

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis

Steffi De Meyer et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

添加到收藏夹

Article Clinical Neurology

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline

Julia Stockmann et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

添加到收藏夹

Article Medicine, General & Internal

Assessment of Plasma Amyloid-β42/40 and Cognitive Decline Among Community-Dwelling Older Adults

Kelly Virecoulon Giudici et al.

JAMA NETWORK OPEN (2020)

添加到收藏夹

Article Clinical Neurology

Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study

Filippo Baldacci et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

添加到收藏夹

Review Medicine, Research & Experimental

Fluid Biomarkers for Synaptic Dysfunction and Loss

Elena Camporesi et al.

BIOMARKER INSIGHTS (2020)

添加到收藏夹

Review Medical Laboratory Technology

Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers

Michelle M. Mielke

JOURNAL OF APPLIED LABORATORY MEDICINE (2020)

添加到收藏夹

Article Clinical Neurology

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease

Philip S. J. Weston et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

添加到收藏夹

Article Clinical Neurology

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease

Carla M. Startin et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

添加到收藏夹

Article Clinical Neurology

Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes

Matthew P. Pase et al.

JAMA NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

Andrea Vergallo et al.

ALZHEIMERS & DEMENTIA (2019)

添加到收藏夹

Review Clinical Neurology

Neurofilament light chain as a biomarker in neurological disorders

Lorenzo Gaetani et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)

添加到收藏夹

Article Clinical Neurology

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

Niklas Mattsson et al.

JAMA NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Lisa Vermunt et al.

ALZHEIMERS & DEMENTIA (2019)

添加到收藏夹

Letter Clinical Neurology

Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy

Floor C. Loonstra et al.

ANNALS OF NEUROLOGY (2019)

添加到收藏夹

Article Neurosciences

Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease

Wei-Wei Li et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

添加到收藏夹

Article Clinical Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

Suzanne E. Schindler et al.

NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Plasma and CSF neurofilament light Relation to longitudinal neuroimaging and cognitive measures

Michelle M. Mielke et al.

NEUROLOGY (2019)

添加到收藏夹

Review Clinical Neurology

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis

Claire Bridel et al.

JAMA NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status

Sebastian Palmqvist et al.

JAMA NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS

Katja Akguen et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)

添加到收藏夹

Review Clinical Neurology

The rights of precision drug development for Alzheimer's disease

Jeffrey Cummings et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

添加到收藏夹

Article Clinical Neurology

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

Ingrid S. van Maurik et al.

LANCET NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease

Zhicheng Chen et al.

ALZHEIMERS & DEMENTIA (2019)

添加到收藏夹

Article Neurosciences

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment

Patrick Oeckl et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

Oliver Preische et al.

NATURE MEDICINE (2019)

添加到收藏夹

Article Clinical Neurology

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease

John C. Morris et al.

JAMA NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

Shannon L. Risacher et al.

ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2019)

添加到收藏夹

Article Clinical Neurology

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

Michelle M. Mielke et al.

ALZHEIMERS & DEMENTIA (2018)

添加到收藏夹

Article Clinical Neurology

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease

Courtney L. Sutphen et al.

ALZHEIMERS & DEMENTIA (2018)

添加到收藏夹

Review Clinical Neurology

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

Clifford R. Jack et al.

ALZHEIMERS & DEMENTIA (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Amyloid blood biomarker detects Alzheimer's disease

Andreas Nabers et al.

EMBO MOLECULAR MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Differences in Obesity Prevalence by Demographic Characteristics and Urbanization Level Among Adults in the United States, 2013-2016

Craig M. Hales et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Clinical Neurology

Plasma tau is increased in frontotemporal dementia

Martha S. Foiani et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)

添加到收藏夹

Article Clinical Neurology

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

Brian A. Gordon et al.

LANCET NEUROLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

High performance plasma amyloid-β biomarkers for Alzheimer's disease

Akinori Nakamura et al.

NATURE (2018)

添加到收藏夹

Article Clinical Neurology

Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study

Saima Hilal et al.

ALZHEIMERS RESEARCH & THERAPY (2018)

添加到收藏夹

Article Clinical Neurology

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes

Inge M. W. Verberk et al.

ANNALS OF NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Juan Fortea et al.

LANCET NEUROLOGY (2018)

添加到收藏夹

Review Clinical Neurology

Neurofilaments as biomarkers in neurological disorders

Michael Khalil et al.

NATURE REVIEWS NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease

Raquel Sanchez-Valle et al.

ALZHEIMERS RESEARCH & THERAPY (2018)

添加到收藏夹

Article Clinical Neurology

Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundacio ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas et al.

ALZHEIMERS RESEARCH & THERAPY (2018)

添加到收藏夹

Review Clinical Neurology

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

Giovanni B. Frisoni et al.

LANCET NEUROLOGY (2017)

添加到收藏夹

Review Clinical Neurology

Review: Astrocytes in Alzheimer's disease and other age-associated dementias: a supporting player with a central role

C. J. Garwood et al.

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2017)

添加到收藏夹

Article Clinical Neurology

Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

Sid E. O'Bryant et al.

ALZHEIMERS & DEMENTIA (2017)

添加到收藏夹

Article Clinical Neurology

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

Vitaliy Ovod et al.

ALZHEIMERS & DEMENTIA (2017)

添加到收藏夹

Article Clinical Neurology

Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort

Jeffrey L. Dage et al.

ALZHEIMERS & DEMENTIA (2016)

添加到收藏夹

Article Clinical Neurology

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Bob Olsson et al.

LANCET NEUROLOGY (2016)

添加到收藏夹

Article Clinical Neurology

The ARIC-PET amyloid imaging study Brain amyloid differences by age, race, sex, and APOE

Rebecca F. Gottesman et al.

NEUROLOGY (2016)

添加到收藏夹

Article Clinical Neurology

Plasma tau in Alzheimer disease

Niklas Mattsson et al.

NEUROLOGY (2016)

添加到收藏夹

Article Clinical Neurology

Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study

Meera Sheffrin et al.

ALZHEIMERS RESEARCH & THERAPY (2016)

添加到收藏夹

Article Clinical Neurology

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

Henrik Zetterberg et al.

JAMA NEUROLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

Magnus Gisslen et al.

EBIOMEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Plasma β-amyloid in Alzheimer's disease and vascular disease

Shorena Janelidze et al.

SCIENTIFIC REPORTS (2016)

添加到收藏夹

Article Cell Biology

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease

Anne M. Fagan et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Letter Clinical Neurology

Plasma tau levels in Alzheimer's disease

Henrik Zetterberg et al.

ALZHEIMERS RESEARCH & THERAPY (2013)

添加到收藏夹

Article Medicine, General & Internal

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

Randall J. Bateman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Urology & Nephrology

Racial and Ethnic Differences in Kidney Function Decline among Persons without Chronic Kidney Disease

Carmen A. Peralta et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)

添加到收藏夹

Article Geriatrics & Gerontology

Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain

J. E. Simpson et al.

NEUROBIOLOGY OF AGING (2010)

添加到收藏夹

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

相关参考文献

导出引文

分享论文